A breakthrough cell therapy is giving new hope to people living with severe, treatment‑resistant lupus. At UCI Health, clinicians are testing an engineered immune cell product designed not just to quiet symptoms but to reset the overactive immune system that drives this chronic autoimmune disease.
Lupus affects an estimated 1.5 million Americans and can damage joints, kidneys, the brain, and other organs, often striking women in their prime years. Many patients cycle through steroids, immunosuppressants, and biologics, only to see partial control at best and mounting side effects over time. For those with moderate to severe systemic lupus erythematosus (SLE) who no longer respond to standard therapies, options have historically been limited.
The new approach being tested at UCI Health uses FT819, a first‑in‑kind CAR T‑cell product developed by Fate Therapeutics. Unlike conventional CAR T treatments that require harvesting and reprogramming each patient’s own T cells, FT819 is manufactured from a stable line of induced pluripotent stem cells, creating an off‑the‑shelf, bioengineered immune therapy. These modified T cells are designed to seek out and eliminate autoreactive B cells that fuel lupus flares and organ damage.
Early signals are striking. One of the first California participants, a 41‑year‑old woman who had battled relentless fevers, joint pain, lupus nephritis, and extreme fatigue for nearly two decades, experienced a dramatic reversal of symptoms within weeks of a single infusion. After years of sleeping up to 18–20 hours a day despite trying “nearly every available therapy,” she became fully functional and able to live a more normal life. Her rheumatologist, Dr. Sheetal De
sai, describes the transformation as both humbling and exhilarating.
The therapy has received a Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, underscoring its potential to change the course of disease rather than provide temporary relief. Participants in this early‑phase trial will be monitored closely for two years to evaluate safety, pharmacokinetics, and durability of remission. The study is funded by the California Institute for Regenerative Medicine and conducted at the UCI Alpha Clinic in collaboration with the Hematopoietic Stem Cell and Cellular Therapy Program, placing it firmly within the growing frontier of regenerative and gene‑based treatments for autoimmune disease.
For people with refractory lupus, this work signals the possibility that one day a single, precisely engineered cell therapy might offer deep, lasting remission—and a chance to reclaim a life long overshadowed by disease
